Case Study
THE OPPORTUNITY
Turning Prescription Decline into Sustained Growth
Declining prescription performance, finishing the year at -1% growth, with increasing pharmacy switching and limited visibility across key systems.
-
Competitive pressures added to challenges with coverage.
-
Pharmacists switching their prescription to an alternative product due to more favorable reimbursement.
-
Many EMR platforms lacked visibility to manufacturer sku’s which impacted point of recommendation follow-though by the doctor.
THE SOLUTION
US Drug and Device Register deployed a targeted commercialization strategy focused on three critical levers:
Pricing Optimization
Conducted a full competitive pricing analysis and restructured the client’s pricing model to better align with market dynamics and stakeholder incentives.
Payer Alignment
Engaged directly with contracted payors to understand disease management priorities and ensure the product strategy supported their clinical and economic goals.
Data & Visibility Fix
Identified gaps in governmental and editorial reporting systems and corrected product data across compendia and reporting agencies—unlocking improved visibility within EMR platforms.
THE RESULT
Achieved +7% growth within 12 months
The results were rapid and measurable:
-
Prescription trends turned positive within 90 days
-
Closed the year at +6% growth, reversing a -1% decline
By aligning pricing, payer strategy, and data visibility, we created a true win-win-win across manufacturers, payors, and providers—reducing pharmacy switching and driving sustained prescription growth.
From Decline to Growth in 90 Days
At a Glance
Company Type:
Small Pharmaceutical Manufacturer
Market:
Prescription Medicine
Challenge:
-1% Full Year Declines
Results:
+7% Full Year Sales Growth
Disclaimer of Warranties and Results
The consulting services, strategies, guidance, and information provided by USDDR are designed to support the improvement of your business operations, performance, and overall efficiency. However, every organization is unique, and actual results will vary based on individual circumstances.
​
USDDR makes no guarantees, promises, or representations regarding specific financial outcomes, revenue increases, business growth, or performance results that may arise from the use of our services. Your success depends on numerous external factors, including market conditions, industry dynamics, internal resources, and your implementation of recommended strategies.
​
By engaging with USDDR, you acknowledge that all business decisions remain your responsibility. USDDR is not liable for any losses, damages, or adverse outcomes resulting from the use or interpretation of our consulting services, recommendations, or materials.
Channels Added
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
Pharmacy | 0 | 1 | 1 | 3 | 7 | 11 | 14 |
GPOs | 0 | 0 | 0 | 2 | 6 | 8 | 10 |
Distributors | 3 | 5 | 6 | 8 | 12 | 15 | 16 |
0
CAGR
0
Days for Positive
Results
CASE STUDIES
A Small Pharmaceutical/OTC Manufacturer saw their growth curve flattened with the latest two months experiencing declines.